Scarica l'app Stockscreener
81.28
0.47%
-0.38
Precedente Chiudi:
$81.66
Aprire:
$81.06
Volume 24 ore:
262.63K
Relative Volume:
0.20
Capitalizzazione di mercato:
$10.91B
Reddito:
$3.10B
Utile/perdita netta:
$586.71M
Rapporto P/E:
18.93
EPS:
4.2937
Flusso di cassa netto:
$605.57M
1 W Prestazione:
+5.96%
1M Prestazione:
+9.90%
6M Prestazione:
-13.88%
1 anno Prestazione:
+29.43%
Intervallo 1D:
$80.40
$82.01
Intervallo di 1 settimana:
$75.43
$81.83
Portata 52W:
$59.51
$101.40
Globus Medical Inc Stock (GMED) Company Profile
Nome
Globus Medical Inc
Settore
Industria
Telefono
610-930-1800
Indirizzo
2560 GENERAL ARMISTEAD AVENUE, AUDUBON, PA
Compare GMED vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GMED
Globus Medical Inc
|
81.28 | 10.91B | 3.10B | 586.71M | 605.57M | 4.2937 |
ABT
Abbott Laboratories
|
103.22 | 178.60B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
95.97 | 122.76B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
307.65 | 118.01B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.37 | 65.74B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.77 | 51.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Globus Medical Inc Stock (GMED) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-07-28 | Iniziato | UBS | Neutral |
| 2026-07-09 | Iniziato | BMO Capital Markets | Outperform |
| 2026-01-30 | Aggiornamento | Needham | Hold → Buy |
| 2026-01-27 | Iniziato | TD Cowen | Buy |
| 2025-11-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-11-07 | Aggiornamento | Truist | Hold → Buy |
| 2025-10-28 | Ripresa | Stifel | Hold |
| 2025-05-27 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-01-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-08-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-03-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-10-20 | Iniziato | ROTH MKM | Buy |
| 2023-09-19 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-02-13 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-02-10 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-02-10 | Downgrade | Loop Capital | Buy → Hold |
| 2023-02-10 | Downgrade | Needham | Buy → Hold |
| 2023-02-10 | Downgrade | Truist | Buy → Hold |
| 2023-02-10 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-04-13 | Ripresa | Truist | Buy |
| 2022-03-28 | Iniziato | Wells Fargo | Overweight |
| 2022-01-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-12-13 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-29 | Iniziato | Loop Capital | Buy |
| 2021-02-18 | Ripresa | Needham | Buy |
| 2020-12-08 | Iniziato | Citigroup | Buy |
| 2020-10-20 | Iniziato | Stifel | Hold |
| 2020-08-06 | Reiterato | Needham | Buy |
| 2020-08-06 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2020-07-21 | Iniziato | Northland Capital | Market Perform |
| 2020-07-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-05-08 | Reiterato | Needham | Buy |
| 2020-03-18 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-01-08 | Iniziato | SunTrust | Buy |
| 2019-12-12 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-08-02 | Reiterato | Needham | Buy |
| 2019-05-24 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2019-05-03 | Reiterato | Needham | Buy |
| 2019-02-28 | Aggiornamento | UBS | Neutral → Buy |
| 2019-01-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-08-02 | Reiterato | Needham | Buy |
| 2018-06-27 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-06-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-05-03 | Reiterato | Needham | Buy |
| 2018-04-04 | Aggiornamento | Needham | Hold → Buy |
Mostra tutto
Globus Medical Inc Borsa (GMED) Ultime notizie
DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally? - Zacks Investment Research
BDX Stock Gains 25.5% in Six Months: What's Behind the Rally? - Zacks Investment Research
DGX Q3 Earnings & Revenues Beat, '26 View Raised, Stock Down in Pre-Market - Zacks Investment Research
GEHC Expands Theranostics Imaging With 5 Global Collaborations - Zacks Investment Research
Revvity Launches Signals LabGistics to Coordinate Scientific Workflows - Zacks Investment Research
Globus Medical (NYSE:GMED): A Balanced Affordable Growth Case - ChartMill
Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm - Morningstar
A Look at Globus Medical Inc (GMED) After 4.4% Gain -- GF Value $97.21 vs Price $78.96 - GuruFocus
Globus Medical Sets November 5 Earnings Report and Call - MyChesCo
Globus Medical, Inc. (GMED) Stock Forecasts - Yahoo! Finance Canada
GMED or AXGN: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Reasons to Add STE Stock to Your Portfolio Right Now - Zacks Investment Research
Haemonetics Gains 149.3% in a Year: What's Driving the Rally? - Zacks Investment Research
Is it Apt to Retain Medtronic Stock in Your Portfolio Now? - Zacks Investment Research
Is Spine Tech Unveiling Altering The Investment Case For Globus Medical Stock? - Yahoo Finance
RBC cuts target to USD 85.00 for Globus Medical stock - ad-hoc-news.de
BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients - Zacks Investment Research
Doximity Deepens U.S. News Alliance to Improve Patient Access to Care - Zacks Investment Research
Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now? - Zacks Investment Research
Is Globus Medical (GMED) Cheap On Its Spine Platform Reveal? - Yahoo Finance
What Does Globus Medical (GMED) Mean For Spine Care After Its NASS 2026 Reveal? - Yahoo Finance
Globus Medical (GMED) Stock Looks Discounted Against Its Earnings Outlook - Yahoo Finance
Globus Medical to Showcase SCRIPT™ Patient-Specific Implants and New XLIF™ Prone Procedural Solution at NASS 2026 - Orthopedics This Week
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? - Zacks Investment Research
Globus Medical, Inc. (GMED.MX) stock price, news, quote and history - Yahoo Finance UK
BTSG Stock Climbs 67.3% YTD: What's Driving the Rally in 2026? - Zacks Investment Research
Reasons to Add QuidelOrtho Stock to Your Portfolio for Now - Zacks Investment Research
Hims & Hers Expands Australian Women's Health Platform With Hers - Zacks Investment Research
A new platform is designed to let surgeons tailor spinal implants to each patient. Globus Medical will preview it at NASS. - Stock Titan
Globus Medical to Showcase SCRIPT™ Patient-Specific Implants and New XLIF™ Prone Procedural Solution at NASS 2026 - GlobeNewswire
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Zacks Investment Research
ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity Matters - Zacks Investment Research
Here's Why You Should Add Avantor Stock to Your Portfolio for Now - Zacks Investment Research
Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms - Zacks Investment Research
Globus Medical to Announce Third Quarter 2026 Financial Results on November 5 and Hold Conference Call - Quiver Quantitative
Globus Medical Schedules Third Quarter Earnings Release and Conference Call - GlobeNewswire
Globus Medical Schedules Third Quarter Earnings Release and Conference Call - Yahoo Finance
Here's Why You Should Retain AMN Stock in Your Portfolio for Now - Zacks Investment Research
Globus Medical Q2 2026 Earnings Call Transcript - Benzinga
How Globus Medical Inc. Class A (GMED) Affects Rotational Strategy Timing - Stock Traders Daily
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y - Zacks Investment Research
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now - Zacks Investment Research
Is it the Right Time to Hold TNDM Stock in Your Portfolio? - Zacks Investment Research
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now - Zacks Investment Research
Globus Medical, Inc. (GMED) Stock Forecasts - Yahoo Finance
Globus Medical, Inc. (GMED) Stock forecasts - Yahoo Finance Singapore
RBC cuts target for Globus Medical stock to USD 85.00 - AD HOC NEWS
Is it the Right Time to Add Phibro Stock to Your Portfolio? - Zacks Investment Research
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets - Zacks Investment Research
Reasons to Retain Hims & Hers Stock in Your Portfolio for Now - Zacks Investment Research
Globus Medical Inc Azioni (GMED) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Globus Medical Inc Azioni (GMED) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| TOBIN JAMES R | Director |
Sep 15 '26 |
Proposed Sale |
74.53 |
30,000 |
2,236,000 |
0 |
| TOBIN JAMES R | Director |
Sep 15 '26 |
Sale |
74.58 |
30,000 |
2,237,502 |
0 |
| ZARRILLI STEPHEN T | Director |
Aug 18 '26 |
Option Exercise |
53.27 |
25,000 |
1,331,750 |
25,000 |
| ZARRILLI STEPHEN T | Director |
Aug 18 '26 |
Sale |
87.04 |
25,000 |
2,175,965 |
0 |
| ZARRILLI STEPHEN T | Director |
Aug 18 '26 |
Proposed Sale |
87.04 |
25,000 |
2,176,000 |
0 |
| Davidar David D | Director |
Jun 05 '26 |
Proposed Sale |
81.00 |
25,000 |
2,025,000 |
0 |
| Davidar David D | Director |
Jun 05 '26 |
Option Exercise |
26.27 |
25,000 |
656,750 |
535,175 |
| Davidar David D | Director |
Jun 05 '26 |
Sale |
80.76 |
25,000 |
2,019,072 |
510,175 |
| RHOADS ANN D | Director |
Jun 04 '26 |
Option Exercise |
26.27 |
25,000 |
656,750 |
40,384 |
| DeFord John A | Former Director |
Apr 14 '26 |
Proposed Sale |
93.10 |
30,000 |
2,793,128 |
0 |
0.04%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):